AMT-116 in Patients With Advanced Solid Tumors

Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Timeline

Start

2023-07-25

Primary completion

2026-12-30

Completion

2026-12-30

Drugs

Indications